Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 12;10(1):43.
doi: 10.3390/brainsci10010043.

Therapeutic Advances for Huntington's Disease

Ashok Kumar  1 , Vijay Kumar  2 , Kritanjali Singh  3 , Sukesh Kumar  4 , You-Sam Kim  2 , Yun-Mi Lee  2 , Jong-Joo Kim  2
Affiliations
Review

Therapeutic Advances for Huntington's Disease

Ashok Kumar et al. Brain Sci. .

Abstract

Huntington's disease (HD) is a progressive neurological disease that is inherited in an autosomal fashion. The cause of disease pathology is an expansion of cytosine-adenine-guanine (CAG) repeats within the huntingtin gene (HTT) on chromosome 4 (4p16.3), which codes the huntingtin protein (mHTT). The common symptoms of HD include motor and cognitive impairment of psychiatric functions. Patients exhibit a representative phenotype of involuntary movement (chorea) of limbs, impaired cognition, and severe psychiatric disturbances (mood swings, depression, and personality changes). A variety of symptomatic treatments (which target glutamate and dopamine pathways, caspases, inhibition of aggregation, mitochondrial dysfunction, transcriptional dysregulation, and fetal neural transplants, etc.) are available and some are in the pipeline. Advancement in novel therapeutic approaches include targeting the mutant huntingtin (mHTT) protein and the HTT gene. New gene editing techniques will reduce the CAG repeats. More appropriate and readily tractable treatment goals, coupled with advances in analytical tools will help to assess the clinical outcomes of HD treatments. This will not only improve the quality of life and life span of HD patients, but it will also provide a beneficial role in other inherited and neurological disorders. In this review, we aim to discuss current therapeutic research approaches and their possible uses for HD.

Keywords: CAG repeat; Huntington’s disease; mutant huntingtin (mHTT); neurodegeneration; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Mechanism of Toxicity of Huntingtin (HTT) gene. NO (Nitric Oxide), CAG (cytosine-adenine-guanine).
Figure 2
Figure 2
Recent advancement in the therapeutics for Huntington’s disease. TBZ (Tetrabenazine); EPA (eicosapentaenoic acid); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); SAHA (suberoylanilide hydroxamic acid); HDACi4b (histone deacetylase inhibitors); RNAi (RNA interference); ASO (antisense oligonucleotide); ZFP (zinc finger protein); CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats); miRNA (micro RNA); siRNA (small interfering RNA).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kim S.D., Fung V.S. An update on Huntington’s disease: From the gene to the clinic. Curr. Opin. Neurol. 2014;27:477–483. doi: 10.1097/WCO.0000000000000116. - DOI - PubMed
    1. Ross C.A., Aylward E.H., Wild E.J., Langbehn D.R., Long J.D., Warner J.H., Scahill R.I., Leavitt B.R., Stout J.C., Paulsen J.S., et al. Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 2014;10:204–216. doi: 10.1038/nrneurol.2014.24. - DOI - PubMed
    1. Lee J.K., Conrad A., Epping E., Mathews K., Magnotta V., Dawson J.D., Nopoulos P. Effect of Trinucleotide Repeats in the Huntington’s Gene on Intelligence. EBioMedicine. 2018;31:47–53. doi: 10.1016/j.ebiom.2018.03.031. - DOI - PMC - PubMed
    1. Sun Y.M., Zhang Y.B., Wu Z.Y. Huntington′s Disease: Relationship Between Phenotype and Genotype. Mol. Neurobiol. 2017;54:342–348. doi: 10.1007/s12035-015-9662-8. - DOI - PubMed
    1. Moss D.J.H., Pardinas A.F., Langbehn D., Lo K., Leavitt B.R., Roos R., Durr A., Mead S., TRACK-HD investigators. REGISTRY investigators et al. Identification of genetic variants associated with Huntington’s disease progression: A genome-wide association study. Lancet Neurol. 2017;16:701–711. doi: 10.1016/S1474-4422(17)30161-8. - DOI - PubMed

LinkOut - more resources